Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role

Journal of the Neurological Sciences

Volumn 287, Issue SUPPL. 1, 2009, Pages

  Liblau, Roland ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Glatiramer acetate; Immune system; Information; Interferon ; Multiple sclerosis; Neuroprotection; T cell

Indexed keywords

BETA INTERFERON; GLATIRAMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; INNATE IMMUNITY; IPEX SYNDROME; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PHENOTYPE; POLYENDOCRINOPATHY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; PEPTIDES; SPINAL CORD;

EID: 72649090947     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)71296-1     Document Type: Article

References (54)

1. Compston A., and Coles A. Multiple sclerosis. Lancet 372 (2008) 1502-1517
2. Barnett M.H., Parratt J.D., Pollard J.D., and Prineas J.W. MS: is it one disease?. Int MS J 16 (2009) 57-65
3. Niino M., Fukazawa T., Kikuchi S., and Sasaki H. Recent advances in genetic analysis of multiple sclerosis: genetic associations and therapeutic implications. Exp Rev Neurotherap 7 (2007) 1175-1188
4. Kieseier B.C., Wiendl H., Leussink V.I., and Stuve O. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol 255 Suppl 6 (2008) 15-21
5. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14599-14606
6. Panitch H.S., Hirsch R.L., Haley A.S., and Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 (1987) 893-895
7. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3 (2002) 291-301
8. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., and Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1 (1971) 242-248
9. Abramsky O., Teitelbaum D., and Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J Neurol Sci 31 (1977) 433-438
10. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317 (1987) 408-414
11. Lisak R.P., Zweiman B., Blanchard N., and Rorke L.B. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci 62 (1983) 281-293
12. Burns J., Krasner L.J., and Guerrero F. Human cellular immune response to copolymer I and myelin basic protein. Neurology 36 (1986) 92-94
13. Burns J., and Littlefield K. Failure of copolymer I to inhibit the human T-cell response to myelin basic protein. Neurology 41 (1991) 1317-1319
14. Brosnan C.F., Litwak M., Neighbour P.A., Lyman W.D., Carter T.H., Bornstein M.B., et al. Immunogenic potentials of copolymer I in normal human lymphocytes. Neurology 35 (1985) 1754-1759
15. Fridkis-Hareli M., and Strominger J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 160 (1998) 4386-4397
16. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 91 (1994) 4872-4876
17. Duda P.W., Krieger J.I., Schmied M.C., Balentine C., and Hafler D.A. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 165 (2000) 7300-7307
18. Aharoni R., Teitelbaum D., Sela M., and Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 91 (1998) 135-146
19. Schrempf W., and Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6 (2007) 469-475
20. Weber M.S., Hohlfeld R., and Zamvil S.S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4 (2007) 647-653
21. Arnon R., and Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14593-14598
22. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13 (2007) 935-943
23. Weber M.S., Starck M., Wagenpfeil S., Meinl E., Hohlfeld R., and Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127 (2004) 1370-1378
24. Kim H.J., Ifergan I., Antel J.P., Seguin R., Duddy M., Lapierre Y., et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 172 (2004) 7144-7153
25. Burger D., Molnarfi N., Weber M.S., Brandt K.J., Benkhoucha M., Gruaz L., et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 106 (2009) 4355-4359
26. Martin D., and Near S.L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 61 (1995) 241-245
27. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 97 (2000) 7452-7457
28. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., and Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105 (2000) 967-976
29. Hestvik A.L., Skorstad G., Price D.A., Vartdal F., and Holmoy T. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 14 (2008) 749-758
30. Aharoni R., Teitelbaum D., Sela M., and Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94 (1997) 10821-10826
31. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100 (2003) 14157-14162
32. Karandikar N.J., Crawford M.P., Yan X., Ratts R.B., Brenchley J.M., Ambrozak D.R., et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 109 (2002) 641-649
33. Tennakoon D.K., Mehta R.S., Ortega S.B., Bhoj V., Racke M.K., and Karandikar N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 176 (2006) 7119-7129
34. Shevach E.M., McHugh R.S., Thornton A.M., Piccirillo C., Natarajan K., and Margulies D.H. Control of autoimmunity by regulatory T cells. Adv Exp Med Biol 490 (2001) 21-32
35. Anderton S.M., and Liblau R.S. Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 21 (2008) 248-254
36. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 172 (2004) 3983-3988
37. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., and Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
38. Josefowicz S.Z., and Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 30 (2009) 616-625
39. van der Vliet H.J., and Nieuwenhuis E.E. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007 (2007) 89017
40. Hong J., Li N., Zhang X., Zheng B., and Zhang J.Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 102 (2005) 6449-6454
41. Taams L.S., and Akbar A.N. Peripheral generation and function of CD4+CD25+ regulatory T cells. Curr Top Microbiol Immunol 293 (2005) 115-131
42. Brenner T., Arnon R., Sela M., Abramsky O., Meiner Z., Riven-Kreitman R., et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 115 (2001) 152-160
43. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 (2002) 2381-2391
44. Ziemssen T., Kumpfel T., Schneider H., Klinkert W.E., Neuhaus O., and Hohlfeld R. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J Neurol Sci 233 (2005) 109-112
45. Chen M., Valenzuela R.M., and Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215 (2003) 37-44
46. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., and Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 125 (2002) 75-85
47. Ziemssen T., Reichmann H., and Schneider H. Presence of glatiramer acetate-specific TH2 cells in the cerebrospinal fluid of patients with multiple sclerosis 12 months after the start of therapy with glatiramer acetate. J Neurodegen Regen 1 (2008) 19-22
48. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., and Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 102 (2005) 19045-19050
49. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Bruck W., et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 105 (2008) 11358-11363
50. Althaus H.H. Remyelination in multiple sclerosis: a new role for neurotrophins?. Prog Brain Res 146 (2004) 415-432
51. Lalive P.H., Paglinawan R., Biollaz G., Kappos E.A., Leone D.P., Malipiero U., et al. TGF-beta-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway. Eur J Immunol 35 (2005) 727-737
52. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101 (2004) 9435-9440
53. Angelov D.N., Waibel S., Guntinas-Lichius O., Lenzen M., Neiss W.F., Tomov T.L., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 100 (2003) 4790-4795
54. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97 (2000) 7446-7451